The role of atypical antipsychotics in bipolar depression and anxiety disorders

Bipolar Disorders, Supplement

Volumn 5, Issue 2, 2003, Pages 20-35

  McIntyre, Roger S ^a   Katzman, Martin ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anxiety; Atypical antipsychotics; Bipolar disorder; Depression; Mania

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM;

ANXIETY DISORDER; APPETITE DISORDER; ASTHENIA; BIPOLAR DEPRESSION; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIAGNOSTIC ERROR; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG RESPONSE; DYSARTHRIA; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FREQUENCY ANALYSIS; GENETIC PREDISPOSITION; HEADACHE; HUMAN; IMPOTENCE; INSOMNIA; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RELAPSE; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; SUICIDE; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; XEROSTOMIA;

EID: 1842556548     PISSN: 13992406     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-2406.2003.00061.x     Document Type: Review

References (125)

1. Suppes T, Dennehy E. Evidence-based long-term treatment of bipolar II disorder. J Clin Psychiatry 2002; 63: 29-33.
2. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50.
3. Judd L, Akiskal H, Schettler P et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II. a clinical spectrum or distinct disorders? J Affect Disord 2003; 73: 19-32.
4. MacQueen G, Young L. Bipolar II disorder: Symptoms, course, and response to treatment. Psychiatr Serv 2001; 52: 358-361.
5. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch General Psychiatry 2001; 58: 844-850.
6. Weissman M, Bland R, Canino G et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276: 293-299.
7. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143-151.
8. Judd L, Akiskal H. The prevalence and disability of bipolar spectrum disorders in the US population: Re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003; 73: 123-131.
9. Cuijpers P, Smit F. Excess mortality in depression: A meta-analysis of community studies. J Affect Disord 2002; 72: 227-236.
10. Penninx B, Geerlings S, Deeg D, van EJ, van TW, Beekman A. Minor and major depression and the risk of death in older persons. Arch General Psychiatry 1999; 56: 889-895.
11. Harris E, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53.
12. Kupfer D, Frank E, Grochocinski V, Cluss P, Houck P, Stapf D. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63: 120-125.
13. Judd L, Akiskal H, Schettler P et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch General Psychiatry 2002; 59: 530-537.
14. Ghaemi S, Sachs G, Chiou A, Pandurangi A, Goodwin K. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord 1999; 52: 135-144.
15. Benazzi F. The Mood Disorder Questionnaire for assessing bipolar spectrum disorder frequency. Can J Psychiatry 2002; 47: 386-387.
16. Hirschfeld R, Calabrese J, Weissman M et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003; 64: 53-59.
17. Lish J, Dime-Meenan S, Whybrow P, Price R, Hirschfeld R. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31: 281-294.
18. Manning J, Haykal R, Connor P, Akiskal H. On the nature of depressive and anxious states in a family practice setting: The high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 1997; 38: 102-108.
19. Ghaemi S, Ko J, Goodwin F. 'Cade's disease' and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002; 47: 125-134.
20. Dilsaver S, Swann A, Shoaib A, Bowers T, Halle M. Depressive mania associated with nonresponse to antimanic agents. Am J Psychiatry 1993; 150: 1548-1551.
21. Kessler R. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: Tohen M, ed. Comorbidity in Affective Disorders. New York: Marcel Dekker, Inc., 1999: 1-25.
22. McElroy S, Strakowski S, Keck PJ, Tugrul K, West S, Lonczak H. Differences and similarities in mixed and pure mania. Compr Psychiatry 1995; 36: 187-194.
23. Himmelhoch J, Garfinkel M. Sources of lithium resistance in mixed mania. Psychopharmacol Bull 1986; 22: 613-620.
24. Perugi G, Toni C, Frare F, Travierso M, Hantouche E, Akiskal H. Obsessive-compulsive-bipolar comorbidity: A systematic exploration of clinical features and treatment outcome. J Clin Psychiatry 2002; 63: 1129-1134.
25. Feske U, Frank E, Mallinger A et al. Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry 2000; 157: 956-962.
26. Enns M, Swenson J, McIntyre R, Swinson R, Kennedy S. Clinical guidelines for the treatment of depressive disorders. VII Comorbidity. Can J Psychiatry 2001; 46 (Suppl. 1): 77S-90S.
27. Tamam L, Ozpoyraz N. Comorbidity of anxiety disorder among patients with bipolar I disorder in remission. Psychopathology 2002; 35: 203-209.
28. McElroy S, Altshuler L, Suppes T et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158: 420-426.
29. Goodwin R, Stayner D, Chinman M, Wu P, Tebes J, Davidson L. The relationship between anxiety and substance use disorders among individuals with severe affective disorders. Compr Psychiatry 2002; 43: 245-252.
30. Cassano G, Pini S, Saettoni M, Dell'Osso L. Multiple anxiety disorder comorbidity in patients with mood spectrum disorders with psychotic features. Am J Psychiatry 1999; 156: 474-476.
31. Young L, Cooke R, Robb J, Levitt A, Joffe R. Anxious and non-anxious bipolar disorder. J Affect Disord 1993; 29: 49-52.
32. Vieta E, Colom F, Martinez-Aran A, Benabarre A, Reinares M, Gasto C. Bipolar II disorder and comorbidity. Compr Psychiatry 2000; 41: 339-343.
33. Johnson J, Cohen P, Brook J. Associations between bipolar disorder and other psychiatric disorders during adolescence and early adulthood: A community-based longitudinal investigation. Am J Psychiatry 2000; 157: 1679-1681.
34. Wozniak J, Biederman J, Monuteaux M, Richards J, Faraone S. Parsing the comorbidity between bipolar disorder and anxiety disorders: A familial risk analysis. J Child Adolesc Psychopharmacol 2002; 12: 101-111.
35. Chen Y, Dilsaver S. Comorbidity for obsessive-compulsive disorder in bipolar and unipolar disorders. Psychiatry Res 1995; 59: 57-64.
36. MacKinnon D, Zandi P, Cooper J et al. Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry 2002; 159: 30-35.
37. MacKinnon D, Xu J, McMahon F et al. Bipolar disorder and panic disorder in families: An analysis of chromosome 18 data. Am J Psychiatry 1998; 155: 829-831.
38. Freeman M, Freeman S, McElroy S. The comorbidity of bipolar and anxiety disorders: Prevalence, psychobiology, and treatment issues. J Affect Disord 2002; 68: 1-23.
39. Hendrick V, Altshuler L, Gitlin M, Delrahim S, Hammen C. Gender and bipolar illness. J Clin Psychiatry 2000; 61: 393-396.
40. Regier D, Farmer M, Rae D et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518.
41. Regier D, Boyd J, Burke J et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch General Psychiatry 1988; 45: 977-986.
42. Brady K, Lydiard R. Bipolar affective disorder and substance abuse. J Clin Psychopharmacol 1992; 12 (Suppl. 1): 17S-22S.
43. Potash J, Kane H, Chiu Y et al. Attempted suicide and alcoholism in bipolar disorder: Clinical and familial relationships. Am J Psychiatry 2000; 157: 2048-2050.
44. Goldberg J, Garno J, Leon A, Kocsis J, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999; 60: 733-740.
45. Sonne S, Brady K. Substance abuse and bipolar comorbidity. Psychiatr Clin North Am 1999; 22: 609-627.
46. Tondo L, Baldessarini R, Hennen J et al. Suicide attempts in major affective disorder patients with comorbid substance use disorders. J Clin Psychiatry 1999; 60 (Suppl. 2): 63-9; discussion, 75-6; 113-116.
47. Levy D, Kimhi R, Barak Y, Aviv A, Elizur A. Antidepressant-associated mania: A study of anxiety disorders patients. Psychopharmacology (Berl) 1998; 136: 243-246.
48. Tondo L, Hennen J, Baldessarini R. Lower suicide risk with long-term lithium treatment in major affective illness: A meta-analysis. Acta Psychiatr Scand 2001; 104: 163-172.
49. Baldessarini R, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. Ann N Y Acad Sci 2001; 932: 24-38.
50. Bowden C. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000; 61 (Suppl. 9): 35-40.
51. Bowden C, Calabrese J, McElroy S et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. The Divalproex Maintenance Study Group. Arch General Psychiatry 2000; 57: 481-489.
52. Denicoff K, Smith-Jackson E, Disney E, Ali S, Leverich G, Post R. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478.
53. Emilien G, Maloteaux J, Seghers A, Charles G. Lithium compared with valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis. Eur Neuropsychopharmacol 1996; 6: 245-252.
54. Calabrese J, Bowden C, Sachs G, Ascher J, Monaghan E, Rudd G. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79-88.
55. Thase M, Sachs G. Bipolar depression: Pharmacotherapy and related therapeutic strategies. Biol Psychiatry 2000; 48: 558-572.
56. Yatham L, Binder C, Kusumakar V, Riccardelli R. Risperidone added to mood stabilizers in mania; is there a difference in effect depending on mood stabilizer? [Abstract P.1.078]. J Eur Coll Neuropsychopharmacol 2002; 12 (Suppl. 3): S202.
57. Vieta E, Gasto C, Colom F et al. Role of risperidone in bipolar II: An open 6-month study. J Affect Disord 2001; 67: 213-219.
58. Vieta E, Goikolea J, Corbella B et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001; 62: 818-825.
59. Yatham L, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141-147.
60. Vieta E, Reinares M, Corbella B et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 2001; 21: 469-473.
61. Tohen M, Vieta E, Kettter T et al. Olanzapine in the treatment of bipolar depression [Abstract P.1.169]. J Eur Coll Neuropsychopharmacol 2002; 12 (Suppl. 3): S238.
62. Dube S, Andersen S, Tohen M et al. Onset of action of olanzapine-fluoxetine combination for bipolar depression [Abstract P.1.077]. J Eur Coll Neuropsychopharmacol 2002; 12 (Suppl. 3): S202.
63. Keck P, Corya S, Case M, Tohen M. Analysis of treatment-emergent mania with olanzapine/fluoxetine combination [Abstract NR475]. Presented at 156th APA Annual Meeting, San Francisco, CA, May 17-22, 2003.
64. Tohen M, Vieta E, Calabrese J et al. Olanzapine/fluoxetine combination and olanzapine in the treatment of bipolar depression [Abstract 16]. Presented at 156th APA Annual Meeting, San Francisco, CA, May 17-22, 2003.
65. Tohen M, Sanger T, McElroy S et al. Olanzapine versus placebo in the treatment of acute mania. The Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702-709.
66. Tohen M, Jacobs T, Grundy S et al. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch General Psychiatry 2000; 57: 841-849.
67. Tohen M, Baker R, Altshuler L et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159: 1011-1017.
68. Tohen M, Chengappa K, Suppes T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch General Psychiatry 2002; 59: 62-69.
69. McIntyre R, Mancini D, McCann S, Srinavasan J, Kennedy S. Antidepressant efficacy and tolerability of risperidone and olanzapine in bipolar disorder [Poster P. 2 E 066]. Int J Neuropsychopharmacol 2002; 5 (Suppl. 1). Available at http://www.cinp2002.com/abstracts/.
70. Fagiolini A, Kupfer D, Houck P, Novick D, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160: 112-117.
71. Zarate C, Rothschild A, Fletcher K, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000; 61: 185-189.
72. Jones M, Huizar K. Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2) [Abstract]. Presented at 156th APA Annual Meeting, San Francisco, CA, May 17-22, 2003.
73. Silverstone P, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001; 62: 523-529.
74. De Nayer A, Geerts S, Ruelens L et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002; 5: 115-120.
75. Davidson J, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety 2002; 16: 4-13.
76. Trivedi M, Rush A, Carmody T et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001; 62: 776-781.
77. Keller M, McCullough J, Klein D et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342: 1462-1470.
78. Ninan P, Rush A, Crits-Christoph P et al. Symptomatic and syndromal anxiety in chronic forms of major depression: Effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry 2002; 63: 434-441.
79. Russell J, Koran L, Rush J et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001; 13: 18-27.
80. Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen J. Efficacy and tolerability of mirtazapine versus citalopram: A double-blind, randomized study in patients with major depressive disorder. The Nordic Antidepressant Study Group, Int Clin Psychopharmacol 1999; 14: 329-337.
81. Tollefson G, Sanger T. Anxious-depressive symptoms in schizophrenia: A new treatment target for pharmacotherapy? Schizophr Res 1999; 35 (Suppl.): S13-S21.
82. Tollefson G, Sanger T, Beasley C, Tran P. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998; 43: 803-810.
83. Peuskens J, van BB, De SC, Lemmens P. Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 2000; 15: 343-349.
84. Stein D, van Seedat S, Van DLG, Zungu-Dirwayi N. Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: A meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000; 15 (Suppl. 2): S31-S39.
85. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts C. Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 860-868.
86. Davidson J, Rothbaum B, van der Kolk B, Sikes C, Farfel G. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch General Psychiatry 2001; 58: 485-492.
87. Eidelman I, Seedat S, Stein D. Risperidone in the treatment of acute stress disorder in physically traumatized in-patients. Depress Anxiety 2000; 11: 187-188.
88. Krashin D, Oates E. Risperidone as an adjunct therapy for post-traumatic stress disorder. Mil Med 1999; 164: 605-606.
89. David D, Defaria L, Lapeyra O, Mellman T. Adjunctive risperidone treatment in combat veterans with chronic PTSD [Abstract 28B]. In: American Psychiatric Association, ed. Syllabus and Scientific Proceedings in Summary Form, Annual Meeting of the American Psychiatric Association. Washington, DC: The Association, 2002. Available at http://www.psych.org/libr_publ/abstracts. htm.
90. Hamner M, Faldowski R, Ulmer H, Frueh B, Huber M, Arana G. Adjunctive risperidone treatment in post-traumatic stress disorder: A preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 2003; 18: 1-8.
91. Bartzokis G, Freeman T, Roca V. Risperidone in the treatment of chronic combat-related post traumatic stress disorder [Abstract P. 2 W 056]. Int J Neuropsychopharmacol 2002; 5 (Suppl. 1): 130.
92. Monnelly E, Ciraulo D, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003; 23: 193-196.
93. Petty F, Brannan S, Casada J et al. Olanzapine treatment for post-traumatic stress disorder: An open-label study. Int Clin Psychopharmacol 2001; 16: 331-337.
94. Butterfield M, Becker M, Connor K, Sutherland S, Churchill L, Davidson J. Olanzapine in the treatment of post-traumatic stress disorder: A pilot study. Int Clin Psychopharmacol 2001; 16: 197-203.
95. Stein M, Kline N, Matloff J. Adjunctive olanzapine for SSRI-resistant combat-related PTSD. A double-blind, placebo-controlled study. Am J Psychiatry 2002; 159: 1777-1779.
96. Kozaric-Kovacic D, Muck-Seler D, Pivac N, Vidosic S, Tomic Z. Olanzapine or fluphenazine in patients with psychotic combat-related posttraumatic stress disorder [Poster P. 2 W 050]. Int J Neuropsychopharmacol 2002; 5 (Suppl. 1). Available at http://www.cinp2002.com/ abstracts/.
97. Hamner M, Deitsch S, Brodrick P, Ulmer H, Lorberbaum J. Quetiapine treatment in patients with posttraumatic stress disorder: An open trial of adjunctive therapy. J Clin Psychopharmacol 2003; 23: 15-20.
98. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002; 22: 309-317.
99. McDougle C, Goodman W, Leckman J, Lee N, Heninger G, Price L. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch General Psychiatry 1994; 51: 302-308.
100. de Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: A prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry 2002; 63: 104-107.
101. Stein D, Bouwer C, Hawkridge S, Emsley R. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58: 119-122.
102. McDougle C, Epperson C, Pelton G, Wasylink S, Price L. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch General Psychiatry 2000; 57: 794-801.
103. Li X, Jackson W, May R, Tolbert L, Baxter L. Risperidone as adjunctive treatment for SSRI-refractory obsessive-compulsive disorder [Abstract 151]. Biol Psychiatry 2002; 51: 51.
104. Arias F, Soto J, Garcia M, Rodríguez-Calvín J, Morales J, Salgado M. Efficacy and tolerance of risperidone addition in serotonin reuptake inhibitors (SRI) treatment for refractory obsessive-compulsive disorder [Abstract P.3.026]. J Eur Coll Neuropsychopharmacol 2002; 12 (Suppl. 3): S341.
105. Pfanner C, Marazziti D, Dell'Osso L et al. Risperidone augmentation in refractory obsessive-compulsive disorder: An open-label study. Int Clin Psychopharmacol 2000; 15: 297-301.
106. Buchsbaum M, Hollander E, Pallanti S, Baldini-Rossi N, Platholi J, Sood E. Positron emission tomography Imaging of risperidone augmentation in SRI-refractory patients [Abstract]. Paper Presented At. Anxiety Disorders Association of America, March 27-30, 2003, Toronto, Canada.
107. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: An open study. Can J Psychiatry 2001; 46: 356-358.
108. Koran L, Ringold A, Elliott M. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000; 61: 514-517.
109. Weiss E, Potenza M, McDougle C, Epperson C. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: An open-label case series. J Clin Psychiatry 1999; 60: 524-527.
110. Peris M, Szerman N. Long-term treatment of obsessive compulsive disorder: Effectiveness of serotonin reuptake inhibitors and olanzapine. New results [Abstract P.3.062]. J Eur Coll Neuropsychopharmacol 2002; 12 (Suppl. 3): S357.
111. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): A 12-week open trial. Psychiatry Res 2000; 96: 91-98.
112. D'Amico G, Cedro C, Muscatello M et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 619-623.
113. Denys D, Van Megen H, Westenberg H. A double-blind, placebo-controlled study of quetiapine addition in treatment refractory patients with OCD [Abstract NR770]. Presented at 156th APA Annual Meeting, San Francisco, CA, May 17-22, 2003.
114. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: A single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002; 17: 115-119.
115. Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: An open-label study. J Clin Psychiatry 2002; 63: 700-703.
116. Maina G, Albert U, Ziero S, Bogetto F. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: What if antipsychotic is discontinued? Int Clin Psychopharmacol 2003; 18: 23-28.
117. Tibbo P, Warneke L. Obsessive-compulsive disorder in schizophrenia: Epidemiologic and biologic overlap. J Psychiatry Neurosci 1999; 24: 15-24.
118. de Haan L, Linszen D, Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenic disorders. J Clin Psychiatry 1999; 60: 364-365.
119. Morrison D, Clark D, Goldfarb E, McCoy L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psychiatry 1998; 155: 855.
120. Mottard J, de la Sablonniere J. Olanzapine-induced obsessive-compulsive disorder. Am J Psychiatry 1999; 156: 799-800.
121. Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): Case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 2001; 26: 55-59.
122. Poyurovsky M, Fuchs C, Weizman A. Obsessive-compulsive disorder in patients with first-episode schizophrenia. Am J Psychiatry 1999; 156: 1998-2000.
123. Ramasubbu R, Ravindran A, Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: Effect of atypical antipsychotic drugs. Pharmacopsychiatry 2000; 33: 236-238.
124. Brawman-Mintzer O. Adjunctive risperidone for treatment resistant general anxiety disorders patients. Facing unmet needs. atypical antipsychotics for mood and anxiety [oral presentation]. Presented at a Satellite Symposium at 156th APA Annual Meeting, San Francisco, CA, May 17-22, 2003.
125. Kinrys G, Nicolaou C, Simon N, Worthington J, Pollack M. Adjunctive olanzapine for treatment refractory generalized anxiety disorder: An interim analysis [Poster P. 4 W 056]. Int J Neuropsychopharmacol 2002; 5 (Suppl. 1). Available at http://www.cinp2002.com/abstracts/.